Chinese investors lead another monster round into this early cancer detection company

Looking to detect cancer early through a simple blood test, Grail Inc. raised a $300 million from several Chinese investors on top of $1.2 billion in two earlier rounds over the past two years. The Menlo Park company, which has been rumored to be planning a $500 million initial public offering in Hong Kong later this year, said the oversubscribed Series C round will help it develop and validate experimental products for early cancer detection. A year ago, it bought Chinese blood diagnos tics company…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news